SVRA: Savara Inc. O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati
Savara Inc. (SVRA) qimmatbaho kamyob kasalliklar dori vositalarini ishlab chiqish tufayli uzoq muddatli xarajatlar xavfga duch kelmoqda, biroq tibbiyot doiralari orasidagi beqayid obro'si ushbu xavotirlarni yumshatadi. PEG momentum ko'rsatkichi ushbu omillarni muvozanatga keltirishga yordam beradi, bunda 0.00 qiymati ushbu metrikaning eng so'nggi ko'rsatkichini aks ettiradi. O'sish istiqbollari molgramostimning kutilayotgan FDA tasdig'i bilan yanada mustahkamlanib, kompaniyani ideal sotib olish maqsadiga aylantirmoqda.
Savara Inc. (SVRA) kompaniyasi koʻrsatkichlari kesimi va tahlili
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- kompaniyaning balans qiymati tafsilotlari:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning kapitalga nisbati Savara Inc.|SVRA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi savarapharma.com|SVRA - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Savara Corp|SVRA - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli qarz hajmi Savara|Tezkor likvidlik koeffitsiyenti savarapharma.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
SVRA - Sof daromad|Kutilayotgan foyda Savara Inc.|SVRA - P/E multiplikatori|Forvard P/E multiplikatori Savara Pharma|SVRA - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Savara Corp|SVRA - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) Savara|SVRA - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi savarapharma.com|SVRA - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Savara Inc.
Kompaniyaning umumiy tahlili:SVRA - Savara Inc
Fundamental jihatdan barqaror aktivlarni aniqlash uchun investorlar PEG koeffitsiyentidan foydalanadilar, u joriy P/E koeffitsiyentini sof foyda o'sish sur'atlari bilan bog'laydi va birdan past qiymat kompaniya qimmatidan past baholanganini anglatadi. Savara Inc. (SVRA) uchun narx-foyda-o'sish koeffitsiyentini tahlil qilish uning aktivlari kam bo'lgan modeli va delegatsiyalangan ishlab chiqarish samaradorligini baholash imkonini beradi hamda bozor qiymati uning R&D loyihalari rivojlanish dinamikasi bilan qanchalik mos kelishini aniqlaydi.
Savara Inc. raqobatchilari
ARGX (argenx N.V.) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori BNTX (BioNTech Group)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Abivax (ABVX)|ADMA - Narxning foydaga va o‘sish sur’atiga nisbati|protagonist-inc.com (PTGX) - Narx-foyda va o‘sish multiplikatori|Immunovant (IMVT) - Narxning foydaga va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori Kiniksa Pharmaceuticals, Ltd.|Narx-foyda va o‘sish multiplikatori GRFS|PEG multiplikatori Adaptive Biotechnologies Inc.|Narxning foydaga va o‘sish sur’atiga nisbati Celldex Therapeutics (CLDX)|auriniapharma.com - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|PEG multiplikatori BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - O‘sish sur’atiga tuzatilgan narx-foyda|DNTH - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Pharvaris Pharma PHVS|ABCL: PEG multiplikatori|tourmalinebio.com (TRML) - PEG multiplikatori|Narx-foyda va o‘sish multiplikatori PGEN|Narxning foydaga va o‘sish sur’atiga nisbati PHAR|PEG multiplikatori NKTR|PEG multiplikatori Upstream Pharma (UPB)|Narxning foydaga va o‘sish sur’atiga nisbati Zenas Biopharma Inc ZBIO|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti IMNM|Gossamer Bio - PEG multiplikatori|KALV - PEG multiplikatori|SEPN (Septerna Corp) - Narx-foyda va o‘sish multiplikatori|Pieris Corp - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|RIGL (Rigel Pharmaceuticals) - PEG multiplikatori|anaptysbio.com (ANAB) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Astria Therapeutics, Inc. (ATXS)|enGene Holdings Inc - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|PEG multiplikatori RAPT (RAPT Therapeutics, Inc.)|JBIO - Narx-foyda va o‘sish multiplikatori|ACRS: Narx-foyda va o‘sish multiplikatori|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati kyvernatx.com KYTX|Tiziana Life Sciences Ltd (TLSA) - Narxning foydaga va o‘sish sur’atiga nisbati|CABA - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narx-foyda va o‘sish multiplikatori VTYX|Narxning foydaga va o‘sish sur’atiga nisbati THTX|Narxning foydaga va o‘sish sur’atiga nisbati Avalo Therapeutics, Inc (AVTX)|ELDN (eledon.com) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori AGEN (Agenus Inc.)|PEG multiplikatori Climb Bio Inc. CLYM|ZURA - Narxning foydaga va o‘sish sur’atiga nisbati|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati ATYR|ADAG: PEG multiplikatori|Ikena Oncology - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|STTK (Shattuck Labs Inc) - PEG multiplikatori|PEG multiplikatori Equillium Bio|Narxning foydaga va o‘sish sur’atiga nisbati Connect Biopharma (CNTB)|IMUX (immunic-therapeutics.com) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narxning foydaga va o‘sish sur’atiga nisbati Atara Bio ATRA|IFRX - Narx-foyda va o‘sish multiplikatori|X4 Pharmaceuticals, Inc. - PEG multiplikatori|ACET - PEG multiplikatori|CELU (celularity.com) - Narx-foyda va o‘sish multiplikatori|INmune Bio Corporation - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|BRNS (Barinthus Biotherapeutics) - PEG multiplikatori|kezarlifesciences.com (KZR) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati SAB Biotherapeutics, Inc. (SABS)|Narx-foyda va o‘sish multiplikatori Akari Therapeutics PLC AKTX|Narxning foydaga va o‘sish sur’atiga nisbati Enlivex Therapeutics Ltd. ENLV|QTTB - Narx-foyda va o‘sish multiplikatori|GOVX: Narx-foyda va o‘sish multiplikatori|EDSA - PEG multiplikatori|iBio (IBIO) - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sishni hisobga olgan narx-foyda koeffitsiyenti CARM|XTLB (XTL Biopharmaceuticals, Ltd.) - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Bolt Bio BOLT|Narxning foydaga va o‘sish sur’atiga nisbati HCW Biologics Inc. (HCWB)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati aptevotherapeutics.com|PEG multiplikatori AIM (AIM ImmunoTech)|PEG multiplikatori Aditxt Inc. ADTX|GRI: Narx-foyda va o‘sish multiplikatori|XRTX: Narxning foydaga va o‘sish sur’atiga nisbati|HIND: PEG multiplikatori|revbiosciences.com (REVB) - PEG multiplikatori|Narxning foydaga va o‘sish sur’atiga nisbati Indaptus Therapeutics, Inc.|SCNI: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori CALI|PEG multiplikatori affimed.com (AFMD)|Allakos - Narx-foyda va o‘sish multiplikatori|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti HOOK|IGM Bio - PEG multiplikatori|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati iTeos Therapeutics Inc ITOS|Ocean Bio (OCEA) - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sishni hisobga olgan narx-foyda koeffitsiyenti TCBP|THRD (Third Harmonic Bio) - PEG multiplikatori
